 |
|
|
|
April 2001 Cover
|
|
Researchers from Vanderbilt University recently concluded a study of the effects of efavirenz in several hundred nucleoside analog reverse transcriptase inhibitor (NRTI) experienced patients. They discovered that the addition of indinavir plus the non-nucleoside
reverse transcriptase inhibitor (NNRTI) efavirenz, results in a significantly lower viral count after more than 24 weeks as compared to strictly the indinavir alone. The positive response was maintained for another 24 weeks. The final study concluded that NRTI
experience patients should be treated with efavirenz, indinavir, and 2 NRTIs as a standard by which alternative treatments should be compared.
Editor's Note: from Reuters Health Info Services
You are not logged in.
No comments yet, but
click here to be the first to comment on this
HIV Digest!
|
|
|
|
|
